FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:658-659 September 7, 1995 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Cytomegalovirus retinitis is a devastating complication that may occur in as many as 40 percent of patients with the acquired immunodeficiency syndrome (AIDS).¹ Lifelong daily intravenous infusions of ganciclovir or foscarnet can usually control cytomegalovirus retinitis,² but these therapies are toxic, expensive, and inconvenient. they are also associated with the risk of catheter-related infection and sepsis. An orally administered anticytomegalovirus drug has therefore been a major goal.

In this issue of the Journal, Drew and associates³ describe an important study of oral ganciclovir for the treatment of cytomegalovirus retinitis. The results, which corroborate those of other investigators,⁴ suggest that the . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.